High Incidence of Anal Human Papillomavirus Infection in HIV-infected Solid Organ Transplant Recipients

    loading  Checking for direct PDF access through Ovid

Abstract

Introduction

Infection with human papillomavirus (HPV), particularly high-risk types (HR-HPV), is an important cause of anogenital and head and neck cancers among both solid organ transplant recipients and HIV-infected patients. There is little data in dually-immunosuppressed HIV-infected transplant patients. We aimed to determine the prevalence, incidence and determinants of anal HPV infection in this population.

Methods

We enrolled HIV-infected patients in a multi-center study prior to transplantation. We collected baseline demographic, medical and behavioral information. We assessed anal HPV6/11/16/18/31/33/35/39/45/51/52/56/58/59 DNA by polymerase chain reaction at baseline, then at 6, 12 and 24 months post-transplant.

Results

Of 86 HIV-infected patients, 90% were male, 53% were men who had sex with men (MSM), 79% were white; 66% underwent liver and 34% kidney transplantation. The median age was 49 (IQR, 44-54). Nineteen percent reported a prior opportunistic infection, and 48% were Hepatitis C (HCV) infected. The median CD4+ prior to transplantation was 172 (IQR, 252-563). At baseline, 71% were infected with anal HPV and 38% were infected with HR-HPV. In a multivariable model, MSM behavior was associated with baseline HR-HPV (OR 3.0, 95% CI, 1.2-7.5). Among liver recipients, HCV infection was associated with lower HR-HPV prevalence (OR 0.2, 95% CI 0.1-0.7). Of those HR-HPV uninfected at the time of transplantation, 5% (95% CI, 1-28); 43% (95% CI, 25-66) and 67% (95% CI, 43-90) were infected by 6, 12 and 24 months post-transplant.

Conclusions

Anal HPV-infection is common in a pre-transplant population of immune reconstituted HIV-infected patients. Even if not present at the time of transplantation, by 2 years, 67% of patients had incident anal HR-HPV detected. Efforts to vaccine eligible patients prior to transplantation and anal cancer screening programs should be prioritized.

Conclusions

National Institues of Allergy and Infectious Diseases (AI052748).

Related Topics

    loading  Loading Related Articles